23 June 2017 - Portola Pharmaceuticals today announced the U.S. FDA has approved Bevyxxa (betrixaban), the first and only anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for venous thromboembolism.

Bevyxxa, an oral, once-daily Factor Xa inhibitor, was granted a fast track designation and approved by the FDA under priority review, which is a status given to drugs that may offer significant improvements in treatment or provide a treatment where no adequate therapy exists. Bevyxxa has been approved based on data from Portola's pivotal Phase 3 APEX Study, which enrolled 7,513 patients at more than 450 clinical sites worldwide.

Read Portola Pharmaceuticals press release